U.S. Markets closed

Aziyo Biologics, Inc. (AZYO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.99-0.63 (-4.03%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.62
Open15.42
Bid12.89 x 900
Ask15.59 x 1100
Day's Range14.99 - 15.90
52 Week Range10.55 - 18.00
Volume15,148
Avg. Volume40,138
Market Cap153.289M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
  • Surgalign Holdings Announce the Commercial Launch of ViBone® Moldable and the First Clinical Implantation
    GlobeNewswire

    Surgalign Holdings Announce the Commercial Launch of ViBone® Moldable and the First Clinical Implantation

    Commercial launch of ViBone® Moldable, a next generation moldable cellular bone matrix product in the USDEERFIELD, Ill., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the application of digital technologies to improve patient outcomes, today announced the commercial launch and the completion of the first surgery of ViBone Moldable in the US. The first implantation was completed by Dr. Adam Crowl, at OrthoVirgina in Midlothian, VA. ViBone Moldable is the newest orthobiologics solution of Surgalign’s bone graft portfolio to support spinal fusion, which currently include ViBone and other advanced bone graft solutions. More about ViBone MoldableViBone Moldable, provided by Aziyo Biologics, Inc. (Nasdaq: AZYO) is a next-generation viable cell bone matrix processed using a proprietary method optimized to protect and preserve the health of native bone cells to potentially enhance new bone formation. It contains cancellous bone particles as well as demineralized cortical bone fibers and particles, delivering the necessary components for bone formation along with excellent handling and cohesive properties. “The moldable and cohesive handling properties of ViBone Moldable are excellent,” said Dr. Crowl and added, “with this, I am able to pack the disc space more densely compared to the other available bone graft options which increases my confidence that the interbody space is well packed and primed for fusion.”“We are excited about the commercial launch and the first clinical use of ViBone Moldable,” said Terry Rich, President and Chief Executive Officer of Surgalign Holdings. “With this addition we have strengthened Surgalign’s biologics portfolio to better serve our surgeon customers and patients. As we introduce new, advanced biologic products to our portfolio, we are well positioned to grow our business and provide better procedurally integrated products in each operating room.”About Surgalign Holdings, Inc.Surgalign Holdings, Inc. is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company is building off a legacy of high quality and differentiated products, and continues to invest in clinically validated innovation to deliver better surgical outcomes and improve patient’s lives.  Surgalign markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors.  Surgalign, a member of AdvaMed, is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Marquette, MI, and Wurmlingen, Germany. Learn more at www.surgalign.com and connect on LinkedIn and Twitter.Forward Looking StatementThis communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in Surgalign’s and Aziyo’s public filings with the U.S. Securities and Exchange Commission (SEC). Actual results may differ materially from the anticipated results reflected in these forward-looking statements.Surgalign Investor Contact: Jonathon Singer Investor and Media Contact jsinger@surgalign.com +1 224 303 4651

  • What You Need To Know About Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Investor Composition
    Simply Wall St.

    What You Need To Know About Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Investor Composition

    A look at the shareholders of Aziyo Biologics, Inc. ( NASDAQ:AZYO ) can tell us which group is most powerful. Insiders...

  • Aziyo Biologics Reports Third Quarter 2020 Financial Results
    GlobeNewswire

    Aziyo Biologics Reports Third Quarter 2020 Financial Results

    SILVER SPRING, Md., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and nine months ended September 30, 2020. Recent Highlights * Recorded net sales of $11.8 million for the third quarter of 2020, representing a 6% increase over the third quarter of 2019 * 31% growth in Core Products over Q3 2019 * Completed initial public offering, raising approximately $43.0 million in net proceeds, after deducting underwriting fees and other expenses * Awarded “breakthrough technology” designation and subsequent group purchasing agreement from Premier Inc. to provide its alliance of approximately 4,100 U.S. hospitals and 200,000 other providers with access to Aziyo’s CanGaroo® Envelope * Expanded partnership with Surgalign Holdings to include the distribution of Aziyo’s ViBone® Moldable, a next generation moldable cellular bone matrix product   “Our third quarter results reflect the strong performance of our Core Products, which showed year-over-year growth in sales over 30%,” said Ron Lloyd, Chief Executive Officer. “Following our initial public offering in October, we are now better positioned financially and operationally to deliver on the opportunity we have in three large markets within regenerative medicine: implantable electronic devices, orthopedic and spine repair, and soft tissue reconstruction. Today, we are addressing this estimated $3 billion market with a comprehensive and growing portfolio of next-generation products driven by an expanding commercial team and partnerships with industry leaders.“Looking ahead, we're especially excited about our strong pipeline of anticipated new product launches, including a growing platform opportunity with CanGaroo to potentially reduce complications associated with a range of implantable electronic devices,” concluded Lloyd.Third Quarter 2020 Financial Results Net sales for the third quarter of 2020 were $11.8 million, an increase of 6%, compared to the third quarter of 2019. The increase was driven primarily by growth of the company’s proprietary Core Products, which delivered sales of $10.3 million, a 31% increase over Q3 2019.Gross profit for the third quarter of 2020 was $5.5 million and gross margin was 47%, as compared to 50% in the corresponding prior-year period. Gross margin, excluding intangible asset amortization (a non-GAAP financial measure) was 54% for the third quarter of 2020, as compared to 57% in the third quarter of 2019. The decrease in gross margin in Q3 2020 primarily resulted from a two-week shutdown of the company’s main production facility, resulting in plant costs being charged directly to cost of goods sold during this shutdown period rather than being a component of inventory, which allowed for the early completion of maintenance activities that would otherwise take place closer to year-end.Total operating expenses were $8.2 million for the third quarter of 2020, as compared to $7.4 million in the corresponding prior year period, an increase of 11%. The increase was driven primarily by investments in research and development and increased general and administrative expenses in anticipation of the company’s initial public offering.Net loss was $6.7 million in the third quarter of 2020, as compared to $3.1 million in the corresponding period of the prior year. Loss per share in the third quarter of 2020, which includes the accretion of deemed dividends to the preferred stockholders, was $15.79 per share, compared to a loss of $4.81 per share in the third quarter of 2019.Cash and cash equivalents were $1.6 million as of September 30, 2020. However, following the end of the third quarter of 2020, Aziyo completed its initial public offering, raising approximately $43.0 million of net proceeds, after deducting underwriting fees and other expenses.Conference Call Aziyo will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Thursday November 19, 2020 to discuss its third quarter 2020 financial results. The call may be accessed through an operator by calling (833) 665-0667 for domestic callers and (914) 987-7319 for international callers using conference ID number 7952289. A live and archived webcast of the event will be available at https://investors.aziyo.com/.  About Aziyo Biologics Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit www.Aziyo.com.         Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements and information concerning the Company’s anticipated financial performance; possible or assumed future results of operations, including descriptions of the Company’s revenues, profitability, outlook and overall business strategy; expectations regarding the Company’s operational position, opportunities and deliverables, goals, strategies, priorities and initiatives, including the expansion of the Company’s commercial team and partnerships; and expectations regarding the Company’s pipeline and anticipated new product launches, including platform opportunities with CanGaroo and the potential results thereof. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Aziyo’s public filings with the Securities and Exchange Commission (“SEC”), including Aziyo’s 424(b)(4) filed on October 8, 2020 in connection with the company’s initial public offering, as updated in Aziyo’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 to be filed with the SEC, and as such factors may be updated from time to time in Aziyo’s other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Aziyo’s website at www.Aziyo.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.Investors: Leigh Salvo or Caroline Paul Gilmartin Group investors@aziyo.com AZIYO BIOLOGICS, INC. CONSOLIDATED BALANCE SHEET DATA (Unaudited, in thousands)AssetsSeptember 30, 2020 December 31, 2019 Current assets:    Cash$1,644  $2,590  Accounts receivable, net 7,096   7,229  Inventory 9,788   7,190  Prepaid expense and other assets 3,685   1,437  Total current assets$22,213  $18,446       Property and equipment, net 1,140   988  Intangible assets, net 22,714   25,262  Other assets 76   76  Total assets$46,143  $44,772            Liabilities, Convertible Preferred Stock and Stockholders' Deficit    Current liabilities:    Accounts payable and accrued expenses$13,542  $8,955  Current portion of long-term debt and revenue interest obligation 5,640   4,442  Revolving line of credit 5,866   4,227  Deferred revenue and other current liabilities 537   650  Total current liabilities 25,585   18,274       Long-term debt 21,201   19,612  Long-term revenue interest obligation 16,667   16,596  Deferred revenue and other long-term liabilities 1,001   952  Total liabilities 64,454   55,434       Convertible preferred stock 56,593   44,449       Stockholders' deficit:    Common stock 1   1  Additional paid-in capital -   1,826  Accumulated deficit (74,905)  (56,938) Total stockholders' deficit (74,904)  (55,111) Total liabilities, convertible preferred stock and stockholders' deficit$46,143  $44,772      AZIYO BIOLOGICS, INC. CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited, in thousands, except share and per share data) Three months ended September 30, Nine months ended September 30,   2020  2019   2020  2019         Net sales$11,774 $11,138  $30,216 $30,847  Cost of goods sold 6,233  5,595   15,676  15,972  Gross profit 5,541  5,543   14,540  14,875         Operating expenses:      Sales and marketing 4,174  4,435   12,471  11,592  General and administrative 3,195  2,448   8,894  6,741  Research and development 863  507   2,811  1,742  Total operating expenses 8,232  7,390   24,176  20,075  Loss from operations (2,691) (1,847)  (9,636) (5,200)        Interest expense 1,465  1,249   4,248  3,935  Other expense, net 2,567  -   2,567  -  Loss before provision of income taxes (6,723) (3,096)  (16,451) (9,135)        Provision for income taxes 8  8   18  21  Net loss (6,731) (3,104)  (16,469) (9,156) Accretion of Convertible Preferred Stock 3,510  -   3,510  -  Net loss attributable to common stockholders$(10,241)$(3,104) $(19,979)$(9,156)        Net loss per share attributable to common stockholders -      basic and diluted$(15.79)$(4.81) $(30.82)$(14.19)        Weighted average common shares outstanding - basic and diluted 648,436  645,142   648,331  645,142    Non-GAAP Financial MeasuresThis press release presents our gross margin, excluding intangible asset amortization. We calculate gross margin, excluding intangible asset amortization, as gross profit, excluding amortization expense relating to intangible assets we acquired in our acquisition of all of the commercial assets of CorMatrix Cardiovascular, Inc. in 2017, divided by net sales. Gross margin, excluding intangible asset amortization, is a supplemental measure of our performance, is not defined by or presented in accordance with U.S. generally accepted accounting principles, (“GAAP”), has limitations as an analytical tool and should not be considered in isolation or as an alternative to our GAAP gross margin, gross profit or any other financial performance measure presented in accordance with GAAP. We present gross margin, excluding intangible asset amortization, because we believe that it provides meaningful supplemental information regarding our operating performance by removing the impact of amortization expense, which is not indicative of our overall operating performance. We believe this provides our management and investors with useful information to facilitate period-to-period comparisons of our operating results. Our management uses this metric in assessing the health of our business and our operating performance, and we believe investors’ understanding of our operating performance is similarly enhanced by our presentation of this metric.Although we use gross margin, excluding intangible asset amortization, as described above, this metric has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may use other measures to evaluate their performance, which could reduce the usefulness of this non-GAAP financial measure as a tool for comparison.The following table presents a reconciliation of our gross margin, excluding intangible asset amortization, to the most directly comparable GAAP financial measure, which is our GAAP gross margin (in thousands). Three months ended September 30, Nine months ended September 30,   2020  2019   2020  2019         Net sales$11,774 $11,138  $30,216 $30,847  Gross profit 5,541  5,543   14,540  14,875  Intangible asset amortization expense 849  849   2,548  2,548  Gross profit, excluding intangible asset amortization$6,390 $6,392  $17,089 $17,424  Gross margin 47% 50%  48% 48% Gross margin percentage, excluding intangible asset amortization 54% 57%  57% 56%